T&R Biofab Co., Ltd. (KOSDAQ:246710)
South Korea
· Delayed Price · Currency is KRW
3,205.00
+75.00 (2.40%)
At close: Mar 6, 2026
T&R Biofab Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Operating Revenue | 20,675 | 4,874 | 5,199 |
| Other Revenue | - | - | -0 |
| Revenue | 20,675 | 4,874 | 5,199 |
| Revenue Growth (YoY) | 297.66% | -6.26% | - |
| Cost of Revenue | 15,425 | 2,766 | 4,151 |
| Gross Profit | 5,250 | 2,108 | 1,048 |
| Selling, General & Admin | 8,922 | 7,230 | 7,024 |
| Research & Development | 3,943 | 5,510 | 4,399 |
| Amortization of Goodwill & Intangibles | 225.28 | 83.77 | 61.8 |
| Other Operating Expenses | 255.92 | 172.15 | 227.69 |
| Operating Expenses | 14,621 | 15,407 | 13,902 |
| Operating Income | -9,371 | -13,299 | -12,853 |
| Interest Expense | -3.46 | -2.2 | -3.24 |
| Interest & Investment Income | 470.21 | 1,227 | 1,676 |
| Currency Exchange Gain (Loss) | -80.49 | 7.49 | 0.97 |
| Other Non Operating Income (Expenses) | 398.35 | 8,044 | -1,424 |
| EBT Excluding Unusual Items | -8,587 | -4,023 | -12,604 |
| Gain (Loss) on Sale of Investments | 1,748 | -517.37 | 5.26 |
| Gain (Loss) on Sale of Assets | 67.39 | -5.8 | -0.14 |
| Asset Writedown | - | - | -195.49 |
| Other Unusual Items | -2,834 | -3,133 | -625.01 |
| Pretax Income | -9,606 | -7,679 | -13,419 |
| Net Income | -9,606 | -7,679 | -13,419 |
| Net Income to Common | -9,606 | -7,679 | -13,419 |
| Shares Outstanding (Basic) | 26 | 26 | 25 |
| Shares Outstanding (Diluted) | 26 | 26 | 25 |
| Shares Change (YoY) | 1.58% | 1.59% | - |
| EPS (Basic) | -371.66 | -297.07 | -527.37 |
| EPS (Diluted) | -371.66 | -297.07 | -527.37 |
| Free Cash Flow | -11,663 | -14,309 | -19,456 |
| Free Cash Flow Per Share | -451.23 | -553.57 | -764.65 |
| Gross Margin | 25.39% | 43.24% | 20.16% |
| Operating Margin | -45.33% | -272.87% | -247.22% |
| Profit Margin | -46.46% | -157.56% | -258.10% |
| Free Cash Flow Margin | -56.41% | -293.60% | -374.22% |
| EBITDA | -5,348 | -10,895 | -10,697 |
| EBITDA Margin | -25.87% | -223.55% | -205.74% |
| D&A For EBITDA | 4,023 | 2,404 | 2,156 |
| EBIT | -9,371 | -13,299 | -12,853 |
| EBIT Margin | -45.33% | -272.87% | -247.22% |
| Advertising Expenses | - | 390.07 | 267.47 |
Source: S&P Capital IQ. Standard template.
Financial Sources.